IDEAYA Biosciences, Inc. $IDYA Shares Bought by DAFNA Capital Management LLC

Key Points

• DAFNA Capital Management LLC increased its stake in IDEAYA Biosciences by **18.1%**, owning 589,330 shares and making it the firm's 11th largest position.
• Several hedge funds have boosted their holdings in IDEAYA, with **Janus Henderson Group PLC** now owning approximately **5.86 million shares**, valued at $150.6 million.
• Analysts have set a **consensus price target of $47.10** for IDEAYA Biosciences, reflecting a predominantly bullish outlook, with nine analysts rating it as a **Buy**.

DAFNA Capital Management LLC increased its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 18.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 589,330 shares of the company's stock after acquiring an additional 90,503 shares during the quarter. IDEAYA Biosciences makes up about 2.7% of DAFNA Capital Management LLC's investment portfolio, making the stock its 11th largest position. DAFNA Capital Management LLC owned approximately 0.67% of IDEAYA Biosciences worth $9,653,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. Janus Henderson Group PLC lifted its stake in IDEAYA Biosciences by 13.5% in the fourth quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock worth $150,606,000 after acquiring an additional 695,263 shares during the period. Vanguard Group Inc. lifted its stake in IDEAYA Biosciences by 0.3% in the first quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company's stock worth $83,417,000 after acquiring an additional 14,535 shares during the period. Deerfield Management Company L.P. Series C lifted its stake in IDEAYA Biosciences by 5.5% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,736,000 shares of the company's stock worth $70,315,000 after acquiring an additional 142,000 shares during the period. Fiera Capital Corp lifted its stake in IDEAYA Biosciences by 2.1% in the first quarter. Fiera Capital Corp now owns 1,209,865 shares of the company's stock worth $19,818,000 after acquiring an additional 25,398 shares during the period. Finally, Bank of America Corp DE lifted its stake in IDEAYA Biosciences by 5.9% in the fourth quarter. Bank of America Corp DE now owns 747,934 shares of the company's stock worth $19,222,000 after acquiring an additional 41,390 shares during the period. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Stock Down 1.5%

Shares of IDYA traded down $0.38 during mid-day trading on Monday, hitting $24.55. 632,810 shares of the company traded hands, compared to its average volume of 865,656. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $40.25. The company has a market capitalization of $2.15 billion, a PE ratio of -6.48 and a beta of 0.12. The business has a 50 day moving average of $23.33 and a 200 day moving average of $20.49.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The firm had revenue of $6.00 million for the quarter, compared to analysts' expectations of $3.48 million. During the same quarter in the prior year, the business posted ($0.68) EPS. The firm's quarterly revenue was up NaN% on a year-over-year basis. As a group, research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Wells Fargo & Company assumed coverage on shares of IDEAYA Biosciences in a report on Thursday, June 26th. They issued an "overweight" rating and a $44.00 target price for the company. JPMorgan Chase & Co. boosted their target price on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a report on Monday, July 28th. The Goldman Sachs Group upgraded shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 target price for the company in a report on Thursday, July 10th. TD Cowen assumed coverage on shares of IDEAYA Biosciences in a report on Tuesday, July 22nd. They issued a "buy" rating for the company. Finally, Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and reduced their target price for the stock from $57.00 to $30.00 in a report on Wednesday, July 9th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $47.10.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.